Literature DB >> 20012939

Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.

K A Toulis, A D Anastasilakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20012939     DOI： 10.1007/s00198-009-1145-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  3 in total

Review 1.  Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

Authors:  A D Anastasilakis; K A Toulis; D G Goulis; S A Polyzos; S Delaroudis; A Giomisi; E Terpos
Journal:  Horm Metab Res       Date:  2009-06-17       Impact factor: 2.936

2.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

3.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Authors:  Georgiana K Ellis; Henry G Bone; Rowan Chlebowski; Devchand Paul; Silvana Spadafora; Judy Smith; Michelle Fan; Susie Jun
Journal:  J Clin Oncol       Date:  2008-08-25       Impact factor: 44.544
  3 in total
  17 in total

1.  Recommendations for preventing fracture in long-term care.

Authors:  Alexandra Papaioannou; Nancy Santesso; Suzanne N Morin; Sidney Feldman; Jonathan D Adachi; Richard Crilly; Lora M Giangregorio; Susan Jaglal; Robert G Josse; Sharon Kaasalainen; Paul Katz; Andrea Moser; Laura Pickard; Hope Weiler; Susan Whiting; Carly J Skidmore; Angela M Cheung
Journal:  CMAJ       Date:  2015-09-14       Impact factor: 8.262

2.  Effects of denosumab on peripheral lymphocyte subpopulations.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Francesco Ghellere; Gaia Tripi; Riccardo Ortolani; Roberta Zanotti; Davide Gatti
Journal:  Endocrine       Date:  2015-08-20       Impact factor: 3.633

3.  Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.

Authors:  Yuyu Li; Zhenqi Shi; Joel Jules; Shenyuan Chen; Robert A Kesterson; Dongfeng Zhao; Ping Zhang; Xu Feng
Journal:  J Bone Miner Res       Date:  2019-08-02       Impact factor: 6.741

Review 4.  Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Authors:  Joel Jules; Jason W Ashley; Xu Feng
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

Review 5.  Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.

Authors:  Jenny A F Vermeer; Greetje A P Renders; Vincent Everts
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 6.  Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

Authors:  Hennie G Raterman; Irene E M Bultink; Willem F Lems
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

Review 7.  Mechanisms involved in normal and pathological osteoclastogenesis.

Authors:  Kyung-Hyun Park-Min
Journal:  Cell Mol Life Sci       Date:  2018-04-18       Impact factor: 9.261

Review 8.  Epidemiology and pathogenesis of osteonecrosis of the jaw.

Authors:  Ian R Reid; Jillian Cornish
Journal:  Nat Rev Rheumatol       Date:  2011-11-29       Impact factor: 20.543

Review 9.  Denosumab: What's new?

Authors:  Cesar E Bogado; Maria Belen Zanchetta; Juan A Boailchuk; Fabio E Massari; Jose R Zanchetta
Journal:  Curr Osteoporos Rep       Date:  2011-03       Impact factor: 5.096

Review 10.  Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review.

Authors:  Takashi Ohnishi; Yuki Ogawa; Kota Suda; Miki Komatsu; Satoko Matsumoto Harmon; Mitsuru Asukai; Masahiko Takahata; Norimasa Iwasaki; Akio Minami
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.